Trulicity Switching Protocols: Moving To and From Dulaglutide Safely

How Dulaglutide Works: The Mechanism Behind Trulicity

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with approximately 90% amino-acid sequence homology to endogenous GLP-1 [7 to 36 amide] [1]. The molecule is engineered as a dimeric fusion protein: two GLP-1 analog chains are each linked to a modified IgG4-Fc fragment, which extends the half-life to roughly 4.7 days and enables once-weekly dosing [2].

Receptor-Level Actions

Binding to the GLP-1 receptor triggers cyclic AMP signaling in pancreatic beta cells, enhancing glucose-dependent insulin secretion and suppressing glucagon release [1]. Because the effect is glucose-dependent, insulin secretion drops off as plasma glucose normalizes, which limits hypoglycemia risk compared with sulfonylureas.

GLP-1 receptors also exist in the hypothalamus, brainstem, gastric smooth muscle, and cardiac tissue [3]. Central receptor activation reduces appetite and slows gastric emptying, contributing to the modest weight loss seen across AWARD program trials [4].

Half-Life and Dosing Implications for Switching

The 4.7-day half-life means dulaglutide reaches steady state after approximately 2 to 3 weeks of weekly injections [2]. When switching away from dulaglutide, the outgoing drug remains pharmacologically active for roughly 2 to 3 weeks after the last dose. This overlap period matters clinically: initiating a full titration dose of the replacement agent on the same day as the last dulaglutide injection may increase nausea risk. A pragmatic approach is to time the first dose of the new agent for the week after the last dulaglutide injection, effectively creating a one-week transition gap without a true washout.

Cardiovascular Mechanism

Beyond glycemia, dulaglutide reduces systolic blood pressure by 2 to 4 mmHg and modestly improves lipid profiles [5]. The REWIND trial attributed its 12% relative risk reduction in major adverse cardiovascular events (MACE) partly to these pleiotropic effects, though the exact mechanism remains debated [6].

REWIND Trial: The Core Cardiovascular Evidence

The REWIND trial (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) is the foundational outcomes data for dulaglutide. Published in The Lancet in 2019, REWIND enrolled 9,901 adults with type 2 diabetes who had either established cardiovascular disease or multiple cardiovascular risk factors, making it broader in eligibility than LEADER (liraglutide) or SUSTAIN-6 (semaglutide) [6].

Primary Endpoint Results

Over a median follow-up of 5.4 years, dulaglutide 1.5 mg weekly reduced the composite of nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death by 12% compared with placebo (HR 0.88, 95% CI 0.79 to 0.99, P<0.026) [6]. This was the first GLP-1 receptor agonist trial to demonstrate MACE benefit in a population where roughly 69% of participants had no prior cardiovascular event at baseline, meaning the benefit extended to primary prevention in high-risk patients.

Secondary Endpoints and Renal Data

REWIND also showed a 15% reduction in a composite renal outcome (new macroalbuminuria, sustained 40% decline in eGFR, or renal replacement therapy) with dulaglutide vs. Placebo (HR 0.85, 95% CI 0.77 to 0.93) [6]. This renal signal supports dulaglutide as a reasonable choice when switching to a GLP-1 agent in patients with early CKD, since no dose adjustment is required regardless of renal function [7].

How REWIND Compares to Competitor Trials

SUSTAIN-6 (N=3,297) tested semaglutide 0.5 mg and 1.0 mg weekly and reported a 26% MACE reduction (HR 0.74, 95% CI 0.58 to 0.95) [8]. The numerically larger relative risk reduction with semaglutide reflects, at least in part, a shorter trial duration (2.1 years), a higher-risk baseline population, and the fact that stroke reduction drove much of the effect. Comparing hazard ratios across these trials is not straightforward and should not be used as the sole basis for switching decisions [6][8].

Switching From Dulaglutide to Semaglutide (Ozempic or Wegovy)

This is the most common switch request in telehealth practice, driven by the superior HbA1c and weight data for semaglutide and by supply availability.

Dose Conversion Guidance

No validated milligram-for-milligram conversion table exists between dulaglutide and semaglutide, because the two molecules have different receptor binding kinetics and potency profiles. The standard clinical approach is to start semaglutide at the lowest approved titration dose and escalate on the labeled schedule:

• Patients on dulaglutide 0.75 mg or 1.5 mg weekly: begin semaglutide at 0.25 mg weekly for 4 weeks, then 0.5 mg, then titrate to effect.
• Patients on dulaglutide 3.0 mg or 4.5 mg weekly who have been stable and GI-tolerant: some clinicians begin at 0.5 mg semaglutide to reduce re-titration time, though evidence for skipping the 0.25 mg step is limited to clinical consensus rather than trial data.

Timing the Switch

Administer the first semaglutide injection one week after the final dulaglutide injection. Giving both drugs within the same 7-day window is not contraindicated, but the additive GI effect makes same-day dosing uncomfortable for most patients. The FDA label for semaglutide (Ozempic) does not specify a washout from other GLP-1 agents [9].

Glycemic Monitoring After the Switch

HbA1c may transiently rise by 0.2 to 0.5% during the semaglutide dose-escalation period (weeks 1 to 16), before the therapeutic dose is reached. Patients with HbA1c above 9.0% at switch initiation should have fasting glucose checked at 4 and 8 weeks. Adjusting background insulin or sulfonylurea at the time of the switch reduces hypoglycemia risk during this transitional window.

Switching From Semaglutide to Dulaglutide

Patients may need to move from semaglutide to dulaglutide due to insurance formulary restrictions, semaglutide shortage, or intolerance to semaglutide's GI profile. Semaglutide's half-life is approximately 7 days, compared to dulaglutide's 4.7 days [2][9].

Starting Dose Selection

Begin dulaglutide at 0.75 mg the week after the last semaglutide dose. If the patient was tolerating semaglutide 0.5 mg or 1.0 mg weekly without GI issues, the prescriber may consider starting at 1.5 mg dulaglutide directly, though the data supporting this step-up are from pharmacokinetic modeling rather than a dedicated head-to-head switching trial.

Efficacy Expectations After Downward Switch

The AWARD-11 trial (N=1,842) tested dulaglutide 4.5 mg weekly and reported a mean HbA1c reduction of 1.6% and mean weight loss of 4.7 kg at 36 weeks [10]. Dulaglutide 1.5 mg produces less weight loss than semaglutide 1.0 mg in head-to-head data from SUSTAIN-7 (N=1,201): semaglutide 1.0 mg reduced body weight by 6.5 kg vs. 3.0 kg for dulaglutide 1.5 mg at 40 weeks [11]. Patients switching from semaglutide to dulaglutide should be counseled that weight loss will likely plateau or partially reverse, and that the highest dulaglutide dose (4.5 mg) minimizes but does not eliminate this gap.

Switching From Dulaglutide to Tirzepatide (Mounjaro or Zepbound)

Tirzepatide is a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 agent, but the practical switching protocol is similar because GLP-1 receptor agonism is a shared mechanism [12].

Dose Mapping

Tirzepatide starting dose is 2.5 mg weekly, regardless of prior GLP-1 dose. The SURPASS-2 trial (N=1,879) compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1.0 mg: tirzepatide 15 mg reduced HbA1c by 2.46% vs. 1.86% for semaglutide, and reduced body weight by 12.4 kg vs. 6.2 kg [13]. Because tirzepatide is considerably more potent per milligram at the GLP-1 receptor (and adds GIP agonism), patients previously stable on dulaglutide 4.5 mg should still begin at 2.5 mg tirzepatide and not attempt to skip the titration schedule.

GI Tolerability During Transition

Nausea rates in SURPASS-2 for tirzepatide 15 mg reached 18% vs. 12% for semaglutide [13]. Patients switching from dulaglutide who have been GI-sensitive should be warned that nausea may increase during the first 4 to 8 weeks of tirzepatide titration, even though they are already GLP-1-experienced. Prescribing a 4-week supply at 2.5 mg before the next prescription is filled is a reasonable way to confirm tolerability.

Switching From Short-Acting GLP-1 Agents (Exenatide, Liraglutide) to Dulaglutide

Exenatide twice-daily (Byetta) and liraglutide once-daily (Victoza) are both shorter-acting agents with different half-lives than dulaglutide.

From Exenatide Twice-Daily

Exenatide has a half-life of approximately 2.4 hours [14]. Because it clears within 24 hours, the patient can take the first dulaglutide 0.75 mg dose the morning after stopping exenatide. No overlap concern exists. The AWARD-1 trial (N=978) compared dulaglutide 1.5 mg to exenatide 10 mcg twice-daily and showed greater HbA1c reduction with dulaglutide (1.51% vs. 0.99%) at 52 weeks [4].

From Liraglutide Once-Daily

Liraglutide's half-life is approximately 13 hours, meaning the drug is essentially cleared within 3 days of stopping. The first dulaglutide injection can follow the last liraglutide dose on any day of the week. Patients who were on liraglutide 1.8 mg can begin dulaglutide at 1.5 mg directly, given demonstrated tolerance of a similar receptor activation intensity.

Switching From Dulaglutide to Weekly Exenatide (Bydureon)

Extended-release exenatide (Bydureon, Bydureon BCise) shares once-weekly dosing with dulaglutide but uses a microsphere delivery system with a slower absorption profile and a longer time to steady state (approximately 6 to 7 weeks) [14]. This switch is infrequent in current practice because dulaglutide shows superior HbA1c reduction in head-to-head data, but formulary constraints occasionally drive it.

Begin extended-release exenatide at 2 mg weekly the week after the last dulaglutide dose. Patients should be counseled that the initial weeks may show less glycemic effect than they experienced with dulaglutide, as the exenatide microspheres have not yet reached steady-state plasma levels [14].

Practical Injection Guidance for Patients Switching Agents

Different GLP-1 devices require different patient education points. Dulaglutide uses a single-use auto-injector with a hidden needle, which many patients find easier than drawing from a vial. Semaglutide (Ozempic) uses a multi-dose pen requiring needle attachment. Tirzepatide (Mounjaro) uses a single-dose auto-injector similar to dulaglutide's.

Injection Site Rotation

All subcutaneous GLP-1 agents should be injected into the abdomen, thigh, or upper arm. Rotating among sites reduces lipohypertrophy, which can slow drug absorption and blunt glycemic response [15]. Patients who report unexpected glycemic worsening after a switch should be asked about injection technique and whether they are reusing needles or injecting into the same site repeatedly.

Storage and Cold-Chain Requirements

Dulaglutide pens may be stored at room temperature (below 30°C / 86°F) for up to 14 days. Semaglutide pens require refrigeration until first use, then may be stored at room temperature for up to 56 days. Tirzepatide pens may be stored at room temperature for up to 21 days [9][12]. These differences matter when counseling patients who travel or lack consistent refrigerator access.

Special Populations: CKD, Heart Failure, and Obesity Without Diabetes

CKD

Dulaglutide requires no dose adjustment for any eGFR level, including patients on dialysis, based on pharmacokinetic data and confirmed in the REWIND renal sub-analysis [6][7]. Semaglutide carries a similar profile. Tirzepatide's label notes limited data in severe CKD but does not mandate dose reduction [12].

Heart Failure

GLP-1 receptor agonists as a class showed no significant benefit and possible harm in patients with preserved ejection fraction heart failure in the LIVE trial and related analyses [16]. The 2023 ACC/AHA Heart Failure Guideline recommends GLP-1 agents for concomitant type 2 diabetes management but does not endorse them as heart failure-specific therapy [17]. Switching between agents in this population follows the same pharmacokinetic principles outlined above, but the prescriber should document the cardiac indication and ensure SGLT2 inhibitor therapy (if indicated) is not displaced by the switch.

Obesity Without Type 2 Diabetes

Dulaglutide does not carry an FDA obesity indication. Semaglutide 2.4 mg weekly (Wegovy) and tirzepatide 2.5 to 15 mg weekly (Zepbound) do [9][12]. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs. 2.4% with placebo [18]. Patients who have been using dulaglutide off-label for weight management and are switched to semaglutide 2.4 mg or tirzepatide for obesity may see substantially greater weight loss, and their antihypertensive or statin regimens may need reassessment.

A Decision Framework for Choosing the Switch Direction

The choice of which GLP-1 agent to switch to (or from dulaglutide) depends on four clinical variables: primary therapeutic goal, cardiovascular history, formulary access, and prior GI tolerance. The table below summarizes the preferred switch direction across common scenarios.

| Clinical Scenario | Preferred Agent After Switch | Starting Dose | Evidence Anchor | |---|---|---|---| | T2D + established ASCVD, cost-sensitive | Dulaglutide 1.5 mg | 0.75 mg x 4 weeks then 1.5 mg | REWIND HR 0.88 [6] | | T2D + need for maximum HbA1c reduction | Tirzepatide | 2.5 mg weekly, titrate | SURPASS-2 [13] | | T2D + obesity, BMI >30, no formulary barrier | Semaglutide 2.4 mg (Wegovy) | 0.25 mg x 4 weeks, titrate | STEP-1 [18] | | T2D + CKD stage 3, cost-sensitive | Dulaglutide 1.5 to 4.5 mg | 0.75 mg x 4 weeks then titrate | REWIND renal [6] | | T2D + prior nausea on semaglutide | Dulaglutide 0.75 mg | 0.75 mg, slow titration | AWARD-1 [4] | | Obesity only (no T2D) | Semaglutide 2.4 mg or tirzepatide 15 mg | Per obesity label | STEP-1 [18], SURMOUNT-1 [19] |

Monitoring Parameters After Any GLP-1 Switch

Three lab values warrant specific attention after switching GLP-1 agents.

Fasting glucose should be checked at 2 and 4 weeks if baseline HbA1c exceeds 9.0% or if the patient is on insulin. HbA1c should be rechecked at 12 weeks after reaching the target dose, not before, because earlier values may underestimate the therapeutic effect of a drug still in titration. Lipase does not require routine surveillance in asymptomatic patients, but persistent upper abdominal pain warrants measurement and temporary drug hold per FDA labeling [9].

Body weight should be documented at each visit during the titration period. A plateau or weight gain within 8 weeks of starting a new GLP-1 agent at an intermediate dose is not a treatment failure; it typically reflects the dose not yet being at therapeutic level. Escalate per label before declaring the switch unsuccessful.